How to Get Semaglutide or Ozempic in Rhode Island

Sources

• Official Patient Guide for Wegovy (semaglutide) Injections: Confirms acceptable injection sites (abdomen, thigh, upper arm), advises keeping injections at least two inches away from the belly button, and provides site hygiene and general device instructions. [Wegovy Patient Guide]
• Novo Nordisk Professional Administration Guide (Wegovy): Details the subcutaneous route into the abdomen, thigh, or upper arm, and advises patients to rotate injection sites. [novoMEDLINK]
• Wegovy Prescribing Information (U.S.): Notes that timing of day and injection site may be changed without dose adjustment; treatment should be administered once weekly on the same day. [Wegovy Prescribing Info]
• Ozempic (semaglutide) – “How to Take” Guide: Reinforces injection site rotation; if using the same area, select a different spot each time. [Ozempic Guide]
• Peer-Reviewed Literature on Lipohypertrophy and Injection Rotation: Explains how consistently rotating sites and spacing injections may lower the risk of lipohypertrophy and improve medication absorption. [PubMed Central]

Important Medical Information and Disclaimers

Medical Disclaimer

This content is for educational purposes only and should not be considered medical advice, diagnosis, or treatment guidance. The U.S. Food and Drug Administration (FDA) has not approved compounded semaglutide for weight management or any other use. Now that the national shortage has ended, federal law generally prohibits pharmacies from compounding products that are essentially copies of FDA-approved medications such as Wegovy. Compounded semaglutide may carry risks related to safety, quality, and dosing accuracy because it does not undergo FDA review for safety, effectiveness, or manufacturing standards. Always consult a qualified healthcare provider before starting or continuing any semaglutide treatment, and obtain prescriptions only for FDA-approved medications dispensed through licensed pharmacies.

Individual Results May Vary

Weight management outcomes with semaglutide can differ significantly from person to person. Clinical trial data may not predict real-world experiences. Factors that influence results include:

• Consistency with prescribed medication use
• Dietary habits and exercise routines
• Metabolic differences
• Other underlying health conditions
• Concurrent medications

No specific outcome or result can be guaranteed.

Important Safety Information

The most commonly reported side effects of semaglutide include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Stomach pain
• Decreased appetite
• Indigestion
• Belching or gas
• Injection site reactions

These side effects are often mild and may lessen over time. Before starting semaglutide, inform your healthcare provider about all medical conditions, allergies, and medications you are currently taking. Ongoing clinical monitoring is recommended during treatment.

Warning: Semaglutide carries a boxed warning regarding the potential risk of thyroid C‑cell tumors. Do not use semaglutide if you or a family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Adverse Event Reporting

If you experience negative side effects from any prescription medication, you are encouraged to report them to the U.S. Food and Drug Administration (FDA) through the MedWatch Adverse Event Reporting Program or by calling 1-800-332-1088. Adverse events may also be reported directly to the medication manufacturer.